Michael Webb

Mr. Michael (Mike) Webb has over 25 years of experience as a founder and CEO of biotechnology companies, advancing them from seed round funding through venture financing and NASDAQ IPO. Mike earned his Bachelor’s degrees in Biochemistry and Economics from the University of Kansas summa cum laude in 1980, his MA in International Relations from Sussex University in 1982, and his MBA with a concentration in healthcare management from the Kellogg Graduate School of Management at Northwestern University in 1984. Currently, he is President and CEO of CXL Ophthalmics, a Phase 3 company developing a novel drug/device combination for the treatment of keratoconus. Previously, he served as the President and CEO of Tyrogenex, a venture-backed company developing an oral treatment for wet age-related macular degeneration (wAMD). As President and CEO of Allegro Diagnostics from [year to year], Mike was instrumental in the development of a novel molecular diagnostic for lung cancer and Allegro’s later acquisition by Veracyte. In 2006, Mr. Webb founded Anchor Therapeutics, a venture-backed company focused on developing a new biology platform for drug discovery, where he also served as CEO. Prior to founding Anchor, Mike led EPIX Pharmaceuticals as CEO (1994-2005) from a venture-backed startup to a publicly traded NASDAQ company, a world leader in the discovery and development of diagnostic imaging agents for MRl, including the first U.S. approved magnetic resonance angiography (MRA) agent, Vasovist®. Before his time at EPIX, Mike was a SVP at CIBA and Senior Consultant at Booz, Allen & Hamilton, specializing in healthcare and life sciences.